Obstetric and Gynecologic Imaging

What Follow-up Imaging Is Best for an Indeterminate Postmenopausal Adnexal Mass?

·
What Follow-up Imaging Is Best for an Indeterminate Postmenopausal Adnexal Mass?

A 68-year-old postmenopausal patient is in your clinic for a follow-up visit. An incidental adnexal mass was noted on a pelvic ultrasound performed for unrelated symptoms. The report describes a 4 cm complex cystic and solid lesion, concluding it is “indeterminate.” The patient is asymptomatic, with no pain, pressure, or abnormal bleeding. You now face the critical decision of how to further evaluate this mass to stratify its risk and determine the need for surgical intervention. This article provides a focused, evidence-based workflow for this exact clinical crossroads. For a postmenopausal patient with an indeterminate adnexal mass on initial ultrasound and no acute symptoms, the American College of Radiology (ACR) rates a follow-up US duplex Doppler pelvis as Usually Appropriate.

Who Fits This Clinical Scenario for an Indeterminate Adnexal Mass?

This guidance is specifically for the follow-up imaging of a postmenopausal adult female with a previously identified adnexal mass that was characterized as indeterminate on an initial pelvic ultrasound. The patient must be clinically stable, with no acute symptoms such as severe, acute-onset pelvic pain, fever, or hemodynamic instability that would suggest an emergent condition like ovarian torsion or a ruptured ectopic pregnancy (though the latter is exceedingly rare in this demographic).

This workflow is distinct from several related but different clinical situations:

  • Premenopausal Patients: The differential diagnosis and risk of malignancy are substantially different in premenopausal women, where functional cysts are common. Their evaluation follows a separate diagnostic algorithm.
  • Masses Deemed “Likely Benign”: If the initial ultrasound confidently characterized the mass as benign (e.g., a simple cyst), the appropriate next step is typically surveillance with serial imaging at longer intervals, not immediate further characterization.
  • Masses “Suspicious for Malignancy”: If the initial ultrasound identified features highly suspicious for cancer (e.g., extensive solid components with florid vascularity, ascites), the workup often proceeds more directly to advanced imaging like MRI or immediate referral to a gynecologic oncologist, bypassing this follow-up step.
  • Initial Imaging: This article addresses the follow-up or problem-solving step after an indeterminate study, not the initial imaging for a clinically suspected mass.

What Diagnoses Are You Working Up in This Scenario?

In a postmenopausal patient, an indeterminate adnexal mass requires a careful workup, with the primary goal of differentiating benign from malignant etiologies. The risk of malignancy for an adnexal mass is significantly higher after menopause.

The foremost concern is epithelial ovarian carcinoma. This is the most common type of ovarian cancer, and its incidence rises with age. Indeterminate features on ultrasound, such as thick septations, solid nodules, or internal blood flow, raise the suspicion for malignancy and are the primary driver for further evaluation. The goal of imaging is to identify these features with greater clarity to guide management.

However, many indeterminate masses are ultimately benign. The differential includes benign neoplasms such as a fibroma, thecoma, or cystadenoma. These tumors can present with complex sonographic features that mimic malignancy, such as solid components (fibroma/thecoma) or internal septations (cystadenoma), making them difficult to distinguish on an initial scan.

Less commonly, an indeterminate adnexal mass could represent a metastasis to the ovary. Cancers of the gastrointestinal tract (Krukenberg tumor), breast, or endometrium can spread to the ovaries and present as a complex adnexal mass.

Finally, non-neoplastic conditions like a hydrosalpinx or a chronic tubo-ovarian complex can appear as complex, cystic adnexal structures that may be difficult to separate from the ovary, leading to an indeterminate initial report.

Why Is Repeat Ultrasound the Recommended Study for This Presentation?

For a postmenopausal patient with an indeterminate adnexal mass, a dedicated follow-up ultrasound, specifically a US duplex Doppler pelvis, is rated Usually Appropriate by the ACR. This includes transvaginal and/or transabdominal approaches as needed. The rationale is grounded in its high diagnostic yield, safety, and accessibility.

A high-quality, targeted follow-up ultrasound performed by an experienced sonographer can often resolve the initial ambiguity. It provides excellent spatial resolution to better assess the internal architecture of the mass, including the thickness of the wall, the presence and complexity of septations, and the morphology of any solid components or papillary projections. Adding Duplex Doppler is critical; it assesses the presence and character of blood flow within the mass. Malignant tumors often exhibit neovascularity, which can be identified as low-resistance arterial flow. The absence of internal flow strongly favors a benign etiology.

This approach is safe and efficient, involving no ionizing radiation (0 mSv) and allowing for direct, real-time comparison with the prior imaging.

Other imaging modalities are rated differently for this specific follow-up scenario:

  • CT pelvis with IV contrast is rated Usually not appropriate. While useful for staging known cancer, CT has inferior soft-tissue contrast resolution compared to ultrasound or MRI for the primary characterization of an adnexal mass. It also exposes the patient to significant ionizing radiation (☢☢☢ 1-10 mSv).
  • FDG-PET/CT is also Usually not appropriate. This modality has a high radiation dose (☢☢☢☢ 10-30 mSv) and is not a first-line tool for characterizing an adnexal mass. It is reserved for staging, assessing treatment response, or detecting recurrence.

It is important to note that MRI pelvis without and with IV contrast is also rated Usually Appropriate. MRI is an outstanding problem-solving tool, offering superior soft-tissue characterization that can often definitively distinguish benign from malignant lesions when ultrasound remains inconclusive. However, given its higher cost and lower accessibility, a high-quality repeat ultrasound is often the most logical and effective first step in the follow-up pathway.

What’s Next After the Follow-up Ultrasound? Downstream Workflow

The results of the follow-up pelvic ultrasound will guide the next steps in management, which typically involves a risk stratification system like the Ovarian-Adnexal Reporting and Data System (O-RADS).

  • If the mass is confidently characterized as benign (e.g., O-RADS 2 or 3): The patient can often be reassured. Depending on the specific findings and size, the next step may be routine annual follow-up or surveillance imaging at a specified interval (e.g., 6-12 months) to ensure stability.
  • If the mass is highly suspicious for malignancy (e.g., O-RADS 5): This finding warrants an urgent referral to a gynecologic oncologist for surgical evaluation. Pre-operative staging with CT of the chest, abdomen, and pelvis may be performed to assess for metastatic disease.
  • If the mass remains indeterminate (e.g., O-RADS 4): This is a common and challenging outcome. For these cases, the next step is often to proceed with the other Usually Appropriate modality: MRI pelvis without and with IV contrast. MRI can clarify the nature of the tissue, such as identifying fat in a dermoid or the characteristic T2-dark appearance of a fibroma, potentially averting surgery. If MRI also remains indeterminate or suspicious, referral to a gynecologic oncologist is necessary.

In all cases, correlation with serum tumor markers, such as CA-125, is a crucial part of the overall risk assessment, though these markers are interpreted in conjunction with imaging findings, not in isolation.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup of an indeterminate adnexal mass requires careful attention to detail to avoid common missteps.

  • Underestimating the value of a high-quality repeat US: Do not assume a second ultrasound will be unhelpful. A dedicated exam by an experienced operator focused on the specific question of characterization can often provide a definitive answer.
  • Prematurely ordering CT: Resist the urge to order a CT for primary characterization. Its radiation dose is significant, and its ability to characterize ovarian tissue is inferior to both ultrasound and MRI.
  • Ignoring patient symptoms: While this workflow is for asymptomatic patients, be vigilant for the development of new symptoms like bloating, pelvic pressure, or weight loss, which could signal a growing or malignant process and should prompt an expedited evaluation.
  • Over-reliance on CA-125: Remember that CA-125 can be elevated in many benign conditions and can be normal in some early-stage ovarian cancers. It is an adjunct to, not a replacement for, high-quality imaging.

If the imaging findings are complex, remain indeterminate after both ultrasound and MRI, or if there is any clinical concern for malignancy, the case should be escalated for discussion at a multidisciplinary tumor board or referred directly to a gynecologic oncologist.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to this topic, please consult the parent guide. For other scenarios or to explore the underlying data, the following GigHz tools are available to support clinical decision-making.

Frequently Asked Questions

Why is MRI also ‘Usually Appropriate’ if ultrasound is the first choice for follow-up?

Both are excellent modalities. Ultrasound is often chosen first for follow-up because it is cost-effective, widely available, and uses no radiation. It can directly compare to the prior US and often resolves the ambiguity. MRI is considered a powerful problem-solving tool with superior soft-tissue contrast. It is typically reserved for cases where the high-quality follow-up ultrasound remains indeterminate, providing a more detailed characterization before proceeding to surgery.

Should I order a CA-125 blood test along with the follow-up ultrasound?

Yes, obtaining a serum CA-125 level is an important part of the risk assessment for a postmenopausal woman with an indeterminate adnexal mass. However, it should be interpreted in conjunction with the imaging findings, as it has limited sensitivity and specificity when used alone. The imaging results and CA-125 level together help inform the overall risk of malignancy and guide the decision for referral to a gynecologic oncologist.

What if the follow-up ultrasound shows a simple cyst? Is further imaging needed?

If the follow-up ultrasound confidently re-characterizes the mass as a simple cyst in a postmenopausal patient, it is considered a benign finding. According to most guidelines, simple cysts up to a certain size (e.g., 5 cm) in this population do not require routine imaging follow-up. Larger simple cysts may warrant a single follow-up scan in 6-12 months to ensure stability.

Does the size of the indeterminate mass change this recommendation?

The general imaging recommendation does not change based on size alone; a follow-up ultrasound is still the appropriate first step. However, the size of the mass is a critical factor in the overall risk assessment. A larger mass, particularly one with solid components, is more concerning and will likely lead to a more aggressive downstream pathway (e.g., proceeding directly to MRI or surgical consultation) if it remains indeterminate on the follow-up ultrasound.

Is a transvaginal ultrasound always necessary for the follow-up?

A transvaginal ultrasound is almost always the preferred component of a pelvic ultrasound for adnexal mass characterization. Its high-frequency transducer provides superior resolution of the ovaries and internal architecture of a mass compared to the transabdominal approach. A transabdominal scan is still performed to get a broader overview of the pelvis and assess for large masses or ascites that might be missed on the transvaginal view alone. The combination is standard practice.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026